✦ LIBER ✦

O.183 Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory, HBeAg(+) chronic hepatitis B patients (ETV-026)

✍ Scribed by C. Yurdaydin; J. Sollano; S. Hadziyannis; S. Kaymakoglu; M. Sherman; H. Brett-Smith; J. Vaughan; R. Hindes

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

80 Entecavir results in continued virolo

✍ C. Yurdaydin; J. Sollano; S. Hadziyannis; S. Kaymakoglu; M. Sherman; H. Brett-Sm 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 102 KB

P.090 Entecavir (ETV) treatment through

✍ R.A. De Man; D. Mutimer; R. Gish; T. Chang; J. Zhu; A. Cross; H. Brett-Smith 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 145 KB

45 Continued virologic and biochemical i

✍ D. Shouval; U.S. Akarca; G. Hatzis; G. Kitis; C.L. Lai; H. Cheinquer; T.T. Chang 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 239 KB

P.082 Entecavir (ETV) treatment through

✍ M. Manns; D. Shouval; U.S. Akarca; G. Hatzis; G. Kitis; R. Zink; J. Zhu; H. Bret 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 133 KB